One of the most curious uses of hemp is as a fence to prevent pollen transfer in commercial production of seeds. Isolation distances for ensuring that seeds produced are pure are considerable for many plants, and often impractical. At one point in the 1980s, the only permitted use of hemp in Germany was as a fence or hedge to prevent plots of beets being used for seed production from being contaminated by pollen from ruderal beets. The high and rather inpenetrable hedge that hemp can produce was considered unsurpassed by any other species for the purpose. As well, the sticky leaves of hemp were thought to trap pollen. However, Saeglitz et al. (2000) demonstrated that the spread of beet pollen is not effectively prevented by hemp hedges. Fiber (i.e. tall) cultivars of hemp were also once used in Europe as wind-breaks, protecting vulnerable crops against wind damage. Although hemp plants can lodge, on the whole very tall hemp is remarkably resistant against wind.
^ Gobbi, Gabriella; Atkin, Tobias; Zytynski, Tomasz; Wang, Shouao; Askari, Sorayya; Boruff, Jill; Ware, Mark; Marmorstein, Naomi; Cipriani, Andrea; Dendukuri, Nandini; Mayo, Nancy (13 February 2019). "Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood". JAMA Psychiatry. doi:10.1001/jamapsychiatry.2018.4500. Retrieved 13 February 2019.
To make matters more confusing, nine states (including California, Washington, and Colorado) let residents buy cannabis-based products with or without THC. Nearly two dozen other “medical marijuana states” allow the sale of cannabis, including capsules, tinctures, and other items containing CBD or THC, at licensed dispensaries to people whose doctors have certified that they have an approved condition (the list varies by state but includes chronic pain, PTSD, cancer, autism, Crohn’s disease, and multiple sclerosis). Sixteen more states legalized CBD for certain diseases. But because all these products are illegal according to the federal government, cannabis advocates are cautious. “By and large, the federal government is looking the other way,” says Paul Armentano, deputy director of the Washington, DC–based National Organization for the Reform of Marijuana Laws (NORML), but until federal laws are changed, “this administration or a future one could crack down on people who produce, manufacture, or use CBD, and the law would be on its side.”
I have read about studies from Europe (not very specific I know) that suggest CBD might work better for some people if combined with some level of THC. Also, the getting high part can be helpful, although not for everybody, of course. A second point – I don’t hear very much about CBD eliminating or almost eliminating pain for people with severe pain. Helpful, but, so far at least, it doesn’t seem that CBDs can replace opioids or substantially reduce pain for all chronic pain patients. Maybe someday.
The other issue with the Medical Marijuana Industry is that they are throwing pain patients under the bus. In order to market their products they are conflating Heroin Addiction, with pain patients taking medically prescribed medications. They overstate the effectiveness for pain control, and present marijuana as a “Cure” for the Opiate Epidemic. They are claiming that Medical Marijuana is a Cure for “Opiate Addiction” in order to sensationalize their claims and make them sound beneficial.
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:
In 2017, the cultivated area for hemp in the Prairie provinces include Saskatchewan with more than 56,000 acres (23,000 ha), Alberta with 45,000 acres (18,000 ha), and Manitoba with 30,000 acres (12,000 ha). Canadian hemp is cultivated mostly for its food value as hulled hemp seeds, hemp oils and hemp protein powders, with only a small fraction devoted to production of hemp fiber used for construction and insulation.
So true. Hearst and Rockefeller did not want Hemp or any form of Cannabis interfering with their lucrative paper, pharmaceutical and oil industries. Hemp is versatile and renewable. It can be used for food, medicine, fuel, paper, clothing, plastic, building materials; just about anything paper and oil is used for. These bastard wealthy people have done a disservice to all people and for the sake of lining their already copiously rich pockets. They and those like them are criminals of the worst order
More recently, Sakamoto and various co-authors have used RAPD to isolate several genetic marker sequences that they name Male-Associated DNA in Cannabis (MADC), and which they interpret as indirect evidence of a male chromosome. Several other research groups have reported identification of male-associated markers using RAPD and AFLP. Ainsworth commented on these findings, stating,
CBD does not appear to have any psychotropic ("high") effects such as those caused by ∆9-THC in marijuana, but may have anti-anxiety and anti-psychotic effects. As the legal landscape and understanding about the differences in medical cannabinoids unfolds, experts are working to distinguish "medical marijuana" (with varying degrees of psychotropic effects and deficits in executive function) – from "medical CBD therapies” which would commonly present as having a reduced or non-psychoactive side-effect profile.
Essential (volatile) oil in hemp is quite different from hempseed oil. Examples of commercial essential oil product products are shown in Fig. 42. The essential oil is a mixture of volatile compounds, including monoterpenes, sesquiterpenes, and other terpenoid-like compounds that are manufactured in the same epidermal glands in which the resin of Cannabis is synthesized (Meier and Mediavilla 1998). Yields are very small—about 10 L/ha (Mediavilla and Steinemann 1997), so essential oil of C. sativa is expensive, and today is simply a novelty. Essential oil of different strains varies considerably in odor, and this may have economic importance in imparting a scent to cosmetics, shampoos, soaps, creams, oils, perfumes, and foodstuffs. Switzerland has been a center for the production of essential oil for the commercial market. Narcotic strains tend to be more attractive in odor than fiber strains, and because they produce much higher numbers of flowers than fiber strains, and the (female) floral parts provide most of the essential oil, narcotic strains are naturally adapted to essential oil production. Switzerland has permitted strains with higher THC content to be grown than is allowed in other parts of the world, giving the country an advantage with respect to the essential oil market. However, essential oil in the marketplace has often been produced from low-THC Cannabis, and the THC content of essential oil obtained by steam distillation can be quite low, producing a product satisfying the needs for very low THC levels in food and other commercial goods. The composition of extracted essential oil is quite different from the volatiles released around the fresh plant (particularly limonene and alpha-pinene), so that a pleasant odor of the living plant is not necessarily indicative of a pleasant-smelling essential oil. Essential oil has been produced in Canada by Gen-X Research Inc., Regina. The world market for hemp essential oil is very limited at present, and probably also has limited growth potential.
Subsequent studies were carried out in different countries, which confirmed the results found in the Zammit et al. (2002) study, showing that those clinically dependent on cannabis by 18 years of age had an increased risk of later developing psychotic symptoms (Fergusson, Horwood, & Swain-Campbell, 2003). Cannabis users were also more likely to develop schizophreniform disorder (Arseneault et al., 2002), and the dose–response relationship found in the first study was confirmed (Henquet et al., 2005).
CBD Oil refers to CBD-infused products that contain CBD suspended in an oily base, such as vegetable glycerin, hempseed oil, or another plant-derived oil. Sublingual oils are ideal because they allow for rapid absorption of CBD through the membrane under your tongue directly into your bloodstream. CBD Oils are available in both low and high doses, and droppers built into the cap make it easy to measure your proper dose. CBD Oils are the most popular kind of CBD product thanks to their ease of use and rapid effects.
A study by Henquet and colleagues (2004) substantially replicated both the Swedish and Dutch studies in a 4-year follow-up of a cohort of 2437 adolescents and young adults between 1995 and 1999 in Munich. They found a dose–response relationship between self-reported cannabis use at baseline and the likelihood of reporting psychotic symptoms. As in the Dutch cohort, young people who reported psychotic symptoms at baseline were much more likely to experience psychotic symptoms at follow-up if they used cannabis than were cannabis-using peers without such a history.
Insomnia: The anxiety-alleviating and sleep-prolonging qualities of CBD oil make it a good option for many people with insomnia. Those who experience insomnia due to pain or discomfort may also find that using CBD oil alleviates their physical symptoms to a noticeable extent. CBD oil may also promote daytime wakefulness when taken in small amounts; people with insomnia can use it as a pick-me-up if they feel excessively tired due to lack of restful sleep.
That’s our two cents worth. We are still reserching products with claims of effective pain relief and possibly something will work. As of right now if dot/gov can not point the now abandoned pain management patient to an effective pain management product, not willing to listen to our physicians or VERY negatively affected patients with a maximum, unilateral dosage of opioid medication new “policy”, then where do we turn for real, effective, pain management?